Savara (NASDAQ:SVRA) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Savara (NASDAQ:SVRA) released its quarterly earnings data on Monday. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.01, reports.

Savara Price Performance

Shares of SVRA traded up $0.18 during mid-day trading on Wednesday, reaching $5.10. 4,789,849 shares of the company’s stock were exchanged, compared to its average volume of 1,774,836. The company has a quick ratio of 10.13, a current ratio of 10.13 and a debt-to-equity ratio of 0.21. Savara has a 52-week low of $4.03 and a 52-week high of $7.01. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -8.80 and a beta of 0.32. The company has a 50-day simple moving average of $4.97 and a two-hundred day simple moving average of $5.35.

Analyst Ratings Changes

SVRA has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a report on Thursday, October 15th. Citigroup reaffirmed a “market outperform” rating on shares of Savara in a report on Wednesday, October 7th. Royal Bank Of Canada set a $10.00 target price on Savara in a research report on Wednesday, October 7th. JPMorgan Chase & Co. initiated coverage on Savara in a report on Wednesday, October 7th. They issued an “overweight” rating and a $12.00 target price on the stock. Finally, Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a research report on Sunday, October 4th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.25.

About Savara

Savara is a biopharmaceutical company focused on developing treatments for serious and rare respiratory diseases. The company is based in the United States and concentrates its research and development efforts on conditions with limited treatment options. Savara’s lead product candidate is molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). It has been developed as a potential treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease in which the buildup of material in the air sacs can impair breathing.